CTOs on the Move

BI Nutraceuticals

www.botanicals.com

 
BI Nutraceuticals is a solutions-based botanical manufacturer, custom contract manufacturer, and supplier to the Dietary Supplement, Food & Beverage, Pharmaceutical, Personal Care, and Pet Care Industries. We are the leading manufacturer of whole herb powders and teas, standardized and drug ratio extracts, vitamins, minerals, amino acids, custom blends, drum-to-hopper (D-T-H) formulations, and granular ingredients. BI Nutraceuticals is committed to providing top-quality ingredients, starting even before the raw material comes through the door with our in-depth industry knowledge and distinguished vendor qualification program. The moment we receive the material it undergoes BI`s Protexx HP™ Green Steam™ sterilization, our patented high pressure, low ...
  • Number of Employees: 100-250
  • Annual Revenue: $10-50 Million
  • www.botanicals.com
  • 2384 East Pacifica Place
    Rancho Dominguez, CA USA 90220
  • Phone: 310.669.2100

Executives

Name Title Contact Details

Similar Companies

Alliant Management Services

Alliant Management Services is a Louisville, KY-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

APAC Partners

APAC Partners is a Dyer, IN-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Spectrum Athletic Clubs

Spectrum Athletic Clubs is one of the leading companies in the Healthcare, Pharmaceuticals, and Biotech sector.

Scryptions International

Scryptions International is a Henderson, NV-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Accord BioPharma

Foresee is a Taiwan and US-based biopharmaceutical company listed on the Taipei Exchange (6576.TWO). Foresee`s R&D efforts are focused in two key areas, namely its unique stabilized injectable formulation (SIF) depot delivery technology with derived drug products targeting specialty markets, and secondly its transformative preclinical and clinical first-in-class NCE programs targeting rare and severe disease areas with high unmet needs. Foresee`s product portfolio includes late stage and early stage programs. CAMCEVI® 42 mg is now approved in the U.S. and under regulatory review in the EU. Additionally, U.S. and EU regulatory submissions are in preparation for CAMCEVI® 21 mg. FP-025 – a highly selective oral MMP-12 inhibitor targeting inflammatory and fibrotic diseases, currently in Phase 2/3 studies, including a Phase 2/3 study for COVID-19 virus-induced acute respiratory distress syndrome (ARDS). FP-045 – a highly selective oral small molecule allosteric activator of ALDH2, a mitochondrial enzyme, for which a Phase 1b/2 study is currently planned for Fanconi Anemia.